Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.10.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2017
Dec. 31, 2016
Current assets    
Cash $ 142 $ 14,305
Prepaid Expenses 3,006
Total current assets 3,148 14,305
Total Assets 3,148 14,305
Current liabilities    
Accounts payable 270,851 349,849
Accrued interest payable 382,302 302,834
Notes payable - current - related parties [1] 630,575 627,022
Notes payable - current - non related parties 163,574 163,574
Derivative liability 180,038
Stock subscription payable 28,081
Related party payables 1,026,819 1,111,754
Other payables 493,164 263,033
Total current liabilities 2,967,285 3,026,185
Total Liabilities 2,967,285 3,026,185
Stockholders' Deficit    
Preferred stock, value
Common stock, $.00001 par value; 800,000,000 shares authorized; 109,409,930 and 67,751,068 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively 1,096 677
Additional paid in capital 14,785,051 14,095,430
Accumulated deficit (17,703,171) (17,064,086)
Total Transbiotec, Inc. stockholders' deficit (2,917,010) (2,967,979)
Noncontrolling interest (47,127) (43,901)
Total Stockholders' Deficit (2,964,137) (3,011,880)
Total Liabilities and Stockholders' Deficit 3,148 14,305
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock, value $ 14
[1] Includes unamortized debt issuance costs related to detached warrants of $19,969 and none at December 31, 2017 and December 31, 2016, respectively.